Gálvez VJR, Álvarez DHT, Cabrera ZJL, Concepción DR, Jay CV

Language: Spanish
References: 15
Page:
PDF size: 127.26 Kb.

ABSTRACT

Polycythemia vera is an abnormal increase in the blood cells, principally in the red blood cells, as a result of an increase of their production in the bone marrow. It is stated that blood is thicker than normal what can slow down the speed of the blood flow through veins and arteries. The objective of this work is to describe the evolution of a patient amputated by critical ischemia, carrier of Polycythemia vera and treated with Heberprot-P^®. We are referring to a 74 years old white male patient with antecedents of ischemic cardiopathy and polycythemia vera that is admitted to the National Institute of Angiology and Vascular Surgery with the diagnosis of critical ischemia of the right foot that caused necrosis of the forefoot. Physical examination was done and the corresponding complementary tests were indicated. It was necessary to perform closed transmetatarsal amputation. During the evolution, he presented necrosis and dehiscence of the wound edges. Surgical debridement was performed and intralesion infiltration of Heberprot-P^®;75 µg began in an ambulatory form 3 times a week. 23 doses were applied. The patient was discharged from outpatient consultation with a 100 % granulation of the lesion and, 15 days later, a complete lock of the transmetatarsal amputation stump was achieved. No adverse reaction was registered during the treatment. Heberprot-P^® is effective in the treatment of a patient with a complex lesion, of different etiology from the ones of ulcers of the diabetic foot.

REFERENCES

1. Domenech E, Marques C. Paciente con pluripatología, úlceras en extremidades inferiores. Rev Esp Med Fam. 2008;6:297-9.

2. Barzan H, Jaff MR, Mannstadt M, Yans S. Case Records of the Massachusetts General Hospital, case 7 2007. A 59 year-old Norman with diabetic senal disease and norhealing skin ulcers. N Engl J Med. 2007;356:104957.

3. Dissemond J, Hoeft D, Knab J, Frankson J, Kroger K, Goos M. Leg ulcer in a patient associated with hidrotyurea therapy. Int J Dermatol. 2006;45:158-60.

4. Hernández Seara A, Cabrera Zamora JL, Viñas Cisneros H, Hondares Guzmán MC, López Díaz M, Licort García E. Caracterización de los pacientes ingresados por isquemia crítica de los miembros inferiores. Rev Cubana Angiol Cir Vasc. 2013 [citado 10 Ene 2013];14(1). Disponible en: http://bvs.sld.cu/revistas/ang/vol14_1_13/angio04113.htm

5. Varela Casariego C, March García JR, de Huro Miralles J, Acir García J. Protocolo terapéutico de la isquemia de miembros inferiores. Medicine. 2009;10(45):3032-5.

6. Faglia E, Clerice G, Clerissi J, Gabriele L, Losa S, Montero M, et al. Long term prognosis M diabetic patients with critical limb ischemia: A population based cohort study. Diabetes Care. 2009;32:8227-30.

7. Paraskeros KI, Beseas N, Papas TT, Gekas CD, Andrikopoulos V, Miknailidis DP. Do different vascular risk factors affect all arteries egually? Angiology. 2008;59(4):397- 401.

8. Labs Kit, Dormandy JA, Jaeger KA, Stuerzehecher C, Heatt WR. Trans Atlantic Conference on Clinical trial guidelines in PAOD (Peripheral arterial occlusive disease) Clinical Trial Methodology. Eng J Vas Endovas Surg. 1999;18:25365.

9. Cabrera Zamora JC, Hernández Seara A, Viña Cisnero H, Hondares Guzmán MC, López Díaz H, Licort García E, et al. Características de las amputaciones mayores en pacientes con isquemia arterial aguda trombótica de miembros inferiores. Rev Cubana Angiol Cir Vasc. 2013 [citado 10 Ene 2013];14(1). Disponible en: http://bvs.sld.cu/revistas/ang/vol14_1_13 /angio03113.htm

10. Hernández Rivero MJ, Llanes Barrios JA, Acosta Lapera DS. Heberprot -P, una terapia eficaz en la prevención de la amputación en el pie diabético. Rev Cubana Angiol Cir Vasc. 2009 [citado 10 Ene 2013];10(1). Disponible en:http://bvs.sld.cu/revistas/ang/vol10_1_09/ang02109.htm

11. Berlanga AJ, Gavilondo CJ, López Saura PA, González LT, Castro SMD, López ME, et al. Epichemil growth factor in clinical practice. A review of its biological actions, clinical indications and safety implications. Int wound J. 2009;c:331-446.

12. Fernández Montequin JI. El arte del desbridamiento en úlceras crónicas. Rev Cubana Angiol Cir Vasc. 2012 [citado 10 Ene 2013];13(1). Disponible en:http://bvs.sld.cu/revistas/ang/vol13_1_12/ang09112.htm

13. Shaw JE, Secree RA, Zimmer PZ. Global Estimate DF. Prevalence of Diabetes for 2010 and Projection for 2030 diabetes. Res Clin Proc. 2009;87(1):4-14.

14. Berlanga AJ. Heberprot P. Antecedente experimentales. Fundamentos farmacológicos y de seguridad. Biotecnologia Aplicada. 2009;1(1):318.

15. Llanes Barrios JA, Álvarez Duarte HT, Toledo Fernández AM, Fernández Montequín JI, Torres Herrera OF, Chirino Carreño N, et al. Manual para la prevención, diagnóstico y tratamiento del pie diabético. Rev Cubana Angiol Cir Vasc. 2009 [citado 10 Ene 2013];10(1):42-96. Disponible en: http://bvs.sld.cu/revistas/ang/vol10_1_09/ang06109.htm